Clinical trials: Endometrium Cancer
Endometrial Cancer, Endometrial Carcinosarcoma
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
This study will test the safety and efficacy of the experimental drug called durvalumab with or without another experimental drug called tremelimumab in endometrial cancer.
- Conditions
- Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent
- Trial name
- NCT03015129
- Testing
- Durvalumab, Tremelimumab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying how well brivanib alaninate works in treating patients with endometrial cancer that has come back (recurred) or is persistent.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma
- Trial name
- NCT00888173
- Testing
- Brivanib Alaninate, Laboratory Biomarker Analysis
- Where
- 35 sites in United States
- Volunteers
- 45 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Cancer Recurrent
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
This was a Phase 2, Simon two-stage, non-randomized, open-label, 2-arm trial of dordaviprone (ONC201) in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen.
- Trial name
- NCT03485729
- Testing
- Dordaviprone (ONC201)
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
Endometrial Cancer
Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer
Multicenter, non-randomized, feasibility study to evaluate the treatment and assess acute safety of the FDA Cleared Axxent Electronic Brachytherapy System and vaginal applicator for intracavitary vaginal cuff treatment according…
- Trial name
- NCT01045187
- Testing
- brachytherapy, Xoft Axxent Electronic Brachytherapy System
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Xoft, Inc.
Endometrial Neoplasms
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer.
- Trial name
- NCT03517449
- Testing
- Pembrolizumab, Lenvatinib, Paclitaxel
- Where
- 169 sites in United States, Argentina and 19 more
- Volunteers
- 827 people
- Sponsor
- Eisai Inc.
Endometrial Neoplasms
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma.
- Trial name
- LEAP-001 (NCT04865289)
- Testing
- Lenvatinib, Pembrolizumab, Paclitaxel
- Where
- 22 sites in China
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Carcinoma
Trisenox® in Women With Metastatic Endometrial Cancer
The primary purpose of this study is to see whether women who have already received chemotherapy for their endometrial cancer, or who have disease that has spread outside of the uterus, will respond to the drug arsenic trioxide…
- Trial name
- NRR (NCT01184053)
- Testing
- Arsenic trioxide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Myeloma, Endometrial Cancer
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
The goal of this proposal is to perform first-in-man evaluation of and experimental imaging agent F-18 tetrafluoroborate (BF4) or (TFB).
- Trial name
- NCT02907073
- Testing
- BF4
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Endometrial Cancer
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
To assess the objective response rate (ORR: complete response + partial response [CR+ PR]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. .
- Trial name
- NCT01111461
- Testing
- Lenvatinib
- Where
- 78 sites in United States, Belgium and 6 more
- Volunteers
- 133 people
- Sponsor
- Eisai Inc.
Breast Cancer, Colorectal Cancer
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial…
- Conditions
- Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer
- Trial name
- AMPLIFY (NCT04000880)
- Testing
- Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health, Diet-Exercise, Exercise-Diet
- Where
- 2 sites in United States
- Volunteers
- 603 people
- Sponsor
- University of Alabama at Birmingham
Endometrial Cancer
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or…
- Trial name
- IXAMPLE2 (NCT00883116)
- Testing
- Ixabepilone, Doxorubicin, Paclitaxel
- Where
- 93 sites in United States, Argentina and 17 more
- Volunteers
- 551 people
- Sponsor
- R-Pharm
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial studies the side effects and how well nintedanib works in treating patients with endometrial cancer that has come back.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01225887
- Testing
- Nintedanib
- Where
- 59 sites in United States
- Volunteers
- 37 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer
- Trial name
- SAVE (NCT03422198)
- Testing
- Vaginal Cuff Brachytherapy, Short course vaginal cuff brachytherapy
- Where
- 5 sites in United States
- Volunteers
- 188 people
- Sponsor
- University of Utah
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT03245736
- Testing
- Tisotumab Vedotin
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Seagen Inc.
Triple Negative Breast Cancer, Endometrial Cancer
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer
- Trial name
- NCT04577963
- Testing
- Fruquintinib, Tislelizumab
- Where
- 16 sites in United States
- Volunteers
- 52 people
- Sponsor
- Hutchmed
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00245050
- Testing
- pyridoxine hydrochloride, doxorubicin HCL liposome
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center